|Bid||78.82 x 100|
|Ask||78.84 x 200|
|Day's Range||80.61 - 82.33|
|52 Week Range||63.76 - 89.54|
|PE Ratio (TTM)||22.99|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||2.28 (2.83%)|
|1y Target Est||88.68|
This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
“We expect to invest over $5 billion in construction and grow this second headquarters to include as many as 50,000 high-paying jobs – it will be a full equal to our current campus in Seattle,” Amazon (AMZN) declares. “In addition to Amazon’s direct hiring and investment, construction and ongoing operation of Amazon HQ2 is expected to create tens of thousands of additional jobs and tens of billions of dollars in additional investment in the surrounding community.” No wonder the finalists want Amazon to come. If Amazon truly wants “to find a city that is excited to work with us,” perhaps it should give special attention to finalist Nashville, Tennessee’s capital, considering that the state treasury lifted its Amazon investment by 33% in the fourth quarter.
For 4Q17, Novartis’s (NVS) Entresto reported sales of $185 million around the world, which represents a YoY (year-over-year) rise of 172% on a reported basis and a 164% YoY rise on a CC (constant currency) basis. Novartis reported Entresto sales of ~$507 million for fiscal 2017, which represents a YoY rise of ~198% on a reported basis. Novartis has now launched Entresto in almost 60 countries worldwide, with its latest launch just completed in China.
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / U.S. markets managed to finish in the green on Friday, despite concerns of rising interest rates and inflationary pressure. The Dow Jones Industrial Average ...
The company reported HCV drug sales of $214 million in the US market, a YoY rise of more than 100%. In 4Q17, international markets contributed ~$296 million to AbbVie’s HCV revenue, a YoY rise of ~14.5% on an operational basis and of 15.4% on a reported basis.
Gilead Sciences, Inc. today announced that Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, R&D and Chief Scientific Officer, and Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2018 Global Healthcare Conference in New York on Wednesday, February 21 at 9:00 a.m.
Valeant Pharmaceuticals (VRX) is a specialty pharmaceutical company involved in the development, manufacture, and marketing of branded, generic, branded generic as well as over the counter products. Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating. Three analysts have given it a “hold” rating, and two analysts have given the stock a “sell” rating.
Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.
Stock Monitor: Gilead Sciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Actinium Pharma, Inc. (NYSE: ATNM ). ...
Gilead popped midday Wednesday after the FDA approved its new HIV regimen — a regimen that could rival treatments from GlaxoSmithKline.
Gilead Sciences Inc.'s once-a-day HIV regimen has been approved by the Food and Drug Administration, the company said Wednesday afternoon. The regimen, Biktarvy, is intended for HIV patients who are new ...
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Biktarvy® , a once-daily single tablet regimen for the treatment of HIV-1 infection.